XNAS
QTTB
Market cap20mUSD
Jun 16, Last price
1.68USD
1D
0.60%
1Q
-21.50%
Name
Q32 Bio Inc
Chart & Performance
P/E
—
P/S
17.34
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.16%
Rev. gr., 5y
-26.32%
Revenues
1m
-82.62%
Net income
-113m
L+163.87%
CFO
-68m
L-29.63%
Earnings
Aug 06, 2025
Profile
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 1,156 -82.62% | 6,651 -80.42% | |||||||
Cost of revenue | 62,580 | 48,475 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (61,424) | (41,824) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 25,881 | 62 | |||||||
Tax Rate | |||||||||
NOPAT | (87,305) | (41,886) | |||||||
Net income | (112,961) 163.87% | (42,809) 13.96% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 42,000 | 184 | 69 | ||||||
BB yield | -0.52% | -0.10% | |||||||
| Debt | |||||||||
Debt current | 3,709 | 1,318 | 32,873 | ||||||
Long-term debt | 21,440 | 19,115 | |||||||
Deferred revenue | 11,318 | ||||||||
Other long-term liabilities | 55,000 | (1) | 111,445 | ||||||
Net debt | (55,416) | (81,335) | (17,719) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (67,715) | (96,230) | (10,957) | ||||||
CAPEX | (75) | (228) | (2,485) | ||||||
Cash from investing activities | 19,925 | 101,326 | (2,466) | ||||||
Cash from financing activities | 95,138 | 184 | 30,069 | ||||||
FCF | (6,442) | (78,789) | (50,849) | ||||||
| Balance | |||||||||
Cash | 77,965 | 82,653 | 43,893 | ||||||
Long term investments | 2,600 | 25,814 | |||||||
Excess cash | 80,565 | 82,595 | 69,374 | ||||||
Stockholders' equity | (234,812) | (542,097) | (133,337) | ||||||
Invested Capital | 314,388 | 616,406 | 169,549 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 3,213 | 3,189 | |||||||
Price | 3.44 -68.57% | 10.94 -51.75% | 22.68 -65.38% | ||||||
Market cap | 35,164 -51.38% | 72,324 -64.06% | |||||||
EV | (46,171) | 55,009 | |||||||
EBITDA | 487 | (60,846) | (41,454) | ||||||
EV/EBITDA | 0.76 | ||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||